Oncology · Phase 3
CLARINET: neuroendocrine tumor progression
What was tested?
Lanreotide versus placebo in people with nonfunctioning enteropancreatic neuroendocrine tumors. ↗
Registered primary question: Time to tumor progression or death, with assessments scheduled through week 96. ↗
What the reviewed report found
Journal year 2014 · Article summary reviewed 2026-09-15
The hazard ratio for progression or death was 0.47 (95% CI 0.30–0.73). Overall survival and quality of life did not differ significantly. Treatment-related diarrhea occurred in 26% versus 9%.↗
Keep in context: The report describes 204 randomized participants; the registry lists 264 enrolled. Improved progression-free survival in this report did not demonstrate improved overall survival. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 264 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2025-03-05; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
CLARINET: neuroendocrine tumors
- Design in the report
- Randomized, double-blind, placebo-controlled trial over 96 weeks.↗
- Participants in the report
- 204 people with advanced nonfunctioning, somatostatin-receptor-positive grade 1 or 2 neuroendocrine tumors; most had stable disease before enrollment.↗
- Limitations
- The selected tumor grades, receptor status and largely stable baseline disease limit generalization. Progression-free survival is distinct from longer overall survival.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours ↗
Protocol identifier: 2-55-52030-726. Sponsor: Ipsen.
Retrieved 2026-09-20; SHA-256 72e108e8bb8670ad9d20a65a3879bc6cd16b0719a2e871c3ac0659e6886a8f13.
PMID 25014687
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 25014687. SHA-256 0e6795be99af1c93f3a3e2726fc8a17152661ca29e8dead110bff36feb856127.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 ba560cbc89f579f1c9993801784e3b4e4720505fa3a71815cb4d17396ad5a315.